Letter regarding article by Mehilli et al, "randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel".
Chaves
Aurea J
AJ
Sousa
Amanda G M R
AG
D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D002985:Clinical Protocols / Q000592:standards; D023903:Coronary Restenosis / Q000209:etiology / Q000517:prevention & control; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology* / Q000627:therapeutic use; D015233:Models, Statistical; D015607:Stents / Q000009:adverse effects*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab